Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/11/2023 | 192.19% | Guggenheim | $46 → $49 | Maintains | Buy |
| 08/14/2023 | 174.3% | Guggenheim | → $46 | Reiterates | Buy → Buy |
| 08/11/2023 | 150.45% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 198.15% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 162.37% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 162.37% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 150.45% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 156.41% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 138.52% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 138.52% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 138.52% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 227.97% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 287.6% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 198.15% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 150.45% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 96.78% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 108.71% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 132.56% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/11/2023 | 192.19% | 古根海姆 | $46→$49 | 維護 | 買 |
| 2023年08月14日 | 174.3% | 古根海姆 | →$46 | 重申 | 購買→購買 |
| 2023年08月11日 | 150.45% | HC Wainwright公司 | $50→$42 | 維護 | 買 |
| 07/26/2023 | 198.15% | HC Wainwright公司 | $44→$50 | 維護 | 買 |
| 07/18/2023 | 162.37% | 威廉·布萊爾 | →$44 | 開始承保 | →跑贏大盤 |
| 2023/06/26 | 162.37% | HC Wainwright公司 | $40→$44 | 維護 | 買 |
| 06/16/2023 | 150.45% | 古根海姆 | $40→$42 | 維護 | 買 |
| 2023年05月18日 | - | 古根海姆 | 開始承保 | →購買 | |
| 05/08/2023 | 156.41% | 奧本海默 | →$43 | 重申 | →跑贏大盤 |
| 03/15/2023 | 138.52% | HC Wainwright公司 | →$40 | 重申 | →購買 |
| 08/01/2022 | 138.52% | 巴克萊 | →$40 | 開始承保 | →超重 |
| 2021/12/21 | 138.52% | HC Wainwright公司 | →$40 | 開始承保 | →購買 |
| 2021年11月23日 | 227.97% | 奧本海默 | →$55 | 開始承保 | →跑贏大盤 |
| 10/08/2021 | 287.6% | 雷蒙德·詹姆斯 | $50→$65 | 維護 | 強勢購買 |
| 2021/06/29 | 198.15% | 雷蒙德·詹姆斯 | $39→$50 | 維護 | 強勢購買 |
| 11/10/2020 | 150.45% | 拉登堡·塔爾曼 | →$42 | 開始承保 | →購買 |
| 11/10/2020 | 96.78% | B of A證券 | →$33 | 開始承保 | →購買 |
| 11/10/2020 | 108.71% | 傑富瑞 | →$35 | 開始承保 | →購買 |
| 11/10/2020 | 132.56% | 雷蒙德·詹姆斯 | →$39 | 開始承保 | →強勢購買 |
What is the target price for Tarsus Pharmaceuticals (TARS)?
塔爾秀克斯製藥公司(Tarsus PharmPharmticals)的目標價是多少？
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Guggenheim on September 11, 2023. The analyst firm set a price target for $49.00 expecting TARS to rise to within 12 months (a possible 192.19% upside). 10 analyst firms have reported ratings in the last year.
古根海姆於2023年9月11日報道了塔爾秀克斯製藥公司(納斯達克代碼：TARS)的最新目標價。這家分析公司將目標價定為49美元，預計TARS將在12個月內升至(可能上漲192.19%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
塔爾秀克斯製藥公司(TARS)最近的分析師評級是多少？
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by Guggenheim, and Tarsus Pharmaceuticals maintained their buy rating.
古根海姆對塔爾秀克斯製藥公司(納斯達克代碼：TRS)的最新分析師評級為買入，塔爾秀克斯製藥公司維持買入評級。
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
塔爾秀克斯製藥公司(TARS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與塔爾秀克斯製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Tarsus製藥的上一次評級是在2023年9月11日提交的，所以你應該預計下一次評級將在2024年9月11日左右的某個時候公佈。
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
分析師對Tarsus PharmPharmticals(TARS)的評級正確嗎？
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $46.00 to $49.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $16.77, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的塔爾秀克製藥(TARS)評級維持不變，目標價在46.00美元至49.00美元之間。塔爾秀克斯製藥公司(Tarsus PharmPharmticals)目前的股價為16.77美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。